Summit Therapeutics Inc. has appointed Dr. Mahkam “Maky” Zanganeh, DDS, MBA as Chief Working Officer, efficient instantly. Dr. Zanganeh is at the moment a member of the Firm’s Board of Administrators, appointed on November 11, 2020.
Dr. Zanganeh joins the corporate from Maky Zanganeh and Associates (MZA), which supplies consulting providers to companies in product improvement, analysis, and transactions, the place she is President and CEO. Previous to founding and main MZA, Dr. Zanganeh held a number of management positions at Pharmacyclics, Inc., from 2008 to 2015, culminating in her function as Chief Working Officer, the place she oversaw all scientific, analysis, business, and business-related issues. Dr. Zanganeh performed a key function within the multimillion-dollar collaboration and license deal for ibrutinib with Janssen Biotech, Inc. in 2011, and the next sale of Pharmacyclics to Abbvie Inc. in 2015.
“Maky’s strategic management and operational experience present immeasurable worth to Summit, as she joins us throughout this important time inside our ongoing Section 3 scientific trials of our precision antibiotic candidate, ridinilazole, the place we search to convey a superior remedy to sufferers with C. difficile an infection,” mentioned Bob Duggan, Govt Chairman and Chief Govt Officer of Summit. “Maky’s confirmed monitor document of translating strategic targets into outcomes will assist propel our Firm as we construct a viable, long-lasting well being care group that improves high quality of life, will increase potential length of life, and resolves medical well being care wants.”